...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Asia-Pacific Biotech News >Inovio Pharmaceuticals to initiate clinical trial for its hepatitis C therapeutic vaccine later this year
【24h】

Inovio Pharmaceuticals to initiate clinical trial for its hepatitis C therapeutic vaccine later this year

机译：Inovio Pharmaceuticals将于今年晚些时候启动其丙型肝炎治疗疫苗的临床试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inovio Pharmaceuticals, Inc. and its development partner VGX International, Inc. will move Inovio's hepatitis C (HCV) DNA vaccine into a Phase l/lla clinical trial by the end of 2013. This advancement is based on outstanding results of a preclinical study which demonstrated for the first time that a multi-antigen SynCon~R HCV vaccine can generate robust T-cell responses not only in the blood but, more importantly, in the liver, an organ known to suppress T-cell activity. VGX International is fundingall preclinical and clinical development. In preparation for entering clinical trials with its HCV vaccine (INO-8000), Inovio has completed manufacturing of its multi-antigen HCV vaccine and is performing IND (Investigational New Drug application)-enabling toxicity testing in animals. INO-8000 is a SynCon HCV therapeutic vaccine targeting NS3/4A, NS4B, and NS5A proteins of HCV. INO-8000 was designed with Inovio's SynCon process to broadly cover HCV genotypes 1a and 1b, the types that have been most difficult to treat with drug therapies.
机译：Inovio Pharmaceuticals，Inc.及其开发合作伙伴VGX International，Inc.将于2013年底前将Inovio的丙型肝炎（HCV）DNA疫苗纳入I / IIa期临床试验。这项进展基于一项临床前研究的杰出结果，首次证明，多抗原SynCon-R HCV疫苗不仅可以在血液中产生更强的T细胞反应，而且更重要的是在肝脏中也能产生抑制T细胞活性的器官。 VGX International正在资助所有的临床前和临床开发。为准备使用其HCV疫苗（INO-8000）进入临床试验，Inovio已完成其多抗原HCV疫苗的生产，并正在进行IND（研究性新药应用）-动物毒性试验。 INO-8000是针对HCV的NS3 / 4A，NS4B和NS5A蛋白的SynCon HCV治疗疫苗。 INO-8000是采用Inovio的SynCon工艺设计的，可广泛覆盖HCV基因型1a和1b，这些基因型是药物治疗中最难治疗的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号